Time filter

Source Type

Patent
Eye Technology Care, French Institute of Health and Medical Research | Date: 2016-10-14

A device for treatment of an ocular pathology characterized in that it comprisesat least one eye ring (1) wherein the proximal end of said eye ring (1) is suitable to be applied onto the globe and means (2,17) to generate ultrasound beam fixed on the distal end of the eye ring (1), said means to generate ultrasound beam presenting a concave segment shape conformed along a single curvature corresponding to a single direction wherein the concavity is designed to be tuned towards the eyeglobe.


Patent
Institute Curie, French National Center for Scientific Research, French Institute of Health, Medical Research, Assistance Publique Hopitaux De Paris and University of Paris Descartes | Date: 2016-07-29

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases.


Patent
French Institute of Health and Medical Research | Date: 2016-11-08

The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.


The invention relates generally to neuroprotection and repair in neurological disorders involving Tan dysfunction (including Alzheimers disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 mid Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tan polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.


Patent
French Institute of Health, Medical Research, Assistance Publique Hopitaux De Paris and Indiana University | Date: 2016-11-17

The present invention relates to methods for preventing and treating chronic kidney disease (CKD).


Patent
French Institute of Health, Medical Research, French National Center for Scientific Research, Genethon, University of Paris Descartes, École Nationale Supérieure de Chimie de Paris, University of Évry Val d'Essonne and Assistance Publique Hopitaux De Paris | Date: 2016-09-16

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA


Patent
French Institute of Health, Medical Research and Montpellier University | Date: 2016-11-21

The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.


Patent
French Institute of Health, Medical Research, Montpellier University, Assistance Publique Hopitaux De Paris, University Paris Est Creteil and University of Angers | Date: 2016-10-17

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.


Patent
French Institute of Health, Medical Research, University Paris Diderot, University of Paris 13 and Assistance Publique Hopitaux De Paris | Date: 2016-11-22

The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.


Patent
Institute Pasteur Paris, French Institute of Health, Medical Research and Assistance Publique Hopitaux De Paris | Date: 2017-04-19

A massive clonal expansion of activated CD8^(+) T-cells with increased frequency of HPV 16-specific CD8^(+) T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.

Loading French Institute of Health and Medical Research collaborators
Loading French Institute of Health and Medical Research collaborators